Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Hormones-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology 4.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Hormones-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology 4.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 6979

Special Issue Editor

Dr. Yasuhiro Miki

E-Mail
Guest Editor
Department of Anatomic Pathology, Tohoku University Graduate School of Medicine 2-1 Seiryo-cho, Aoba-ku, Sendai 981-8575, Miyagi, Japan
Interests: breast cancer; endometrial cancer; tumor microenvironment; intracrine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is well-known that breast and prostate cancers are related to female and male hormones, respectively. Recently, it has been established that male steroid hormones, such as androgen, play an important role in female breast cancer progression. For approximately a dozen years, the possibility of anti-estrogen therapy for both female and male non-small lung carcinoma patients has been a significant area of research. In addition, the peptide hormones released by psychological stress directly stimulate growth signals in solid cancers, such as ovarian and endometrial cancers. Research into hormone-dependent cancers continues to progress at a rapid pace.

This Special Issue of the International Journal of Molecular Sciences entitled “Hormone-Dependent Cancers: New Aspects of Biochemistry and Molecular Pathology 4.0”, will focus on recent advances in hormone and cancer research, such as the molecular action of hormone receptors, biochemical analysis of steroid or peptide hormones, growth or invasive signals of hormone-related cancers, and mechanisms of resistance of endocrine therapy. Contributions on these or related topics are welcome, including original research and full- and mini-reviews. Postdocs, Ph.D. students, and young researchers are all very welcome to contribute.

Dr. Yasuhiro Miki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hormone-related cancer
  • endocrine/intracrine
  • breast
  • prostate
  • endometrium
  • ovary
  • endocrine organs
  • female and male hormones
  • growth hormones
  • steroid hormones
  • peptide hormones
  • hormone receptors
  • biochemical analysis
  • pathophysiology
  • molecular biology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

25 pages, 1367 KiB  
Review
MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection—Narrative Review
by Agata Poniewierska-Baran, Łukasz Zadroga, Edo Danilyan, Paulina Małkowska, Paulina Niedźwiedzka-Rystwej and Andrzej Pawlik
Int. J. Mol. Sci. 2023, 24(6), 5386; https://doi.org/10.3390/ijms24065386 - 11 Mar 2023
Cited by 3 | Viewed by 2036
Abstract
Melanoma is the most serious type of skin cancer, causing a large majority of deaths but accounting for only ~1% of all skin cancer cases. The worldwide incidence of malignant melanoma is increasing, causing a serious socio-economic problem. Melanoma is diagnosed mainly in [...] Read more.
Melanoma is the most serious type of skin cancer, causing a large majority of deaths but accounting for only ~1% of all skin cancer cases. The worldwide incidence of malignant melanoma is increasing, causing a serious socio-economic problem. Melanoma is diagnosed mainly in young and middle-aged people, which distinguishes it from other solid tumors detected mainly in mature people. The early detection of cutaneous malignant melanoma (CMM) remains a priority and it is a key factor limiting mortality. Doctors and scientists around the world want to improve the quality of diagnosis and treatment, and are constantly looking for new, promising opportunities, including the use of microRNAs (miRNAs), to fight melanoma cancer. This article reviews miRNA as a potential biomarker and diagnostics tool as a therapeutic drugs in CMM treatment. We also present a review of the current clinical trials being carried out worldwide, in which miRNAs are a target for melanoma treatment. Full article
(This article belongs to the Special Issue Hormones-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology 4.0)
►▼ Show Figures

Figure 1

26 pages, 729 KiB  
Review
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
by Ekaterina Nevedomskaya and Bernard Haendler
Int. J. Mol. Sci. 2022, 23(11), 6281; https://doi.org/10.3390/ijms23116281 - 03 Jun 2022
Cited by 15 | Viewed by 4283
Abstract
Cancer arises following alterations at different cellular levels, including genetic and epigenetic modifications, transcription and translation dysregulation, as well as metabolic variations. High-throughput omics technologies that allow one to identify and quantify processes involved in these changes are now available and have been [...] Read more.
Cancer arises following alterations at different cellular levels, including genetic and epigenetic modifications, transcription and translation dysregulation, as well as metabolic variations. High-throughput omics technologies that allow one to identify and quantify processes involved in these changes are now available and have been instrumental in generating a wealth of steadily increasing data from patient tumors, liquid biopsies, and from tumor models. Extensive investigation and integration of these data have led to new biological insights into the origin and development of multiple cancer types and helped to unravel the molecular networks underlying this complex pathology. The comprehensive and quantitative analysis of a molecule class in a biological sample is named omics and large-scale omics studies addressing different prostate cancer stages have been performed in recent years. Prostate tumors represent the second leading cancer type and a prevalent cause of cancer death in men worldwide. It is a very heterogenous disease so that evaluating inter- and intra-tumor differences will be essential for a precise insight into disease development and plasticity, but also for the development of personalized therapies. There is ample evidence for the key role of the androgen receptor, a steroid hormone-activated transcription factor, in driving early and late stages of the disease, and this led to the development and approval of drugs addressing diverse targets along this pathway. Early genomic and transcriptomic studies have allowed one to determine the genes involved in prostate cancer and regulated by androgen signaling or other tumor-relevant signaling pathways. More recently, they have been supplemented by epigenomic, cistromic, proteomic and metabolomic analyses, thus, increasing our knowledge on the intricate mechanisms involved, the various levels of regulation and their interplay. The comprehensive investigation of these omics approaches and their integration into multi-omics analyses have led to a much deeper understanding of the molecular pathways involved in prostate cancer progression, and in response and resistance to therapies. This brings the hope that novel vulnerabilities will be identified, that existing therapies will be more beneficial by targeting the patient population likely to respond best, and that bespoke treatments with increased efficacy will be available soon. Full article
(This article belongs to the Special Issue Hormones-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology 4.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop